Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
Oncternal Therapeutics reports developments tied to its oncology drug-development portfolio and corporate transition. The company had developed novel oncology therapies including ONCT-534, a dual-action androgen receptor inhibitor for relapsed or refractory metastatic castration-resistant prostate cancer; ONCT-808, an autologous ROR1-targeting CAR T therapy for aggressive B-cell lymphoma; and zilovertamab, an investigational ROR1 monoclonal antibody.
Recurring news themes include clinical-study updates, safety and efficacy data, financial results, termination of clinical programs, strategic-alternative activity, asset sales and the wind-down of operations.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) will announce its Q1 2021 financial results post-market on May 6, 2021. A webcast led by management will follow at 2:00 PM PT (5:00 PM ET) to discuss the results and provide a business update. Oncternal focuses on developing oncology therapies for critical medical needs, with ongoing clinical trials for cirmtuzumab and TK216. The company's pipeline targets significant cancer pathways, including a combination therapy for mantle cell lymphoma and a targeted inhibitor for Ewing sarcoma.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the presentation of two abstracts at the ASCO 2021 Annual Meeting, scheduled for June 4-8, 2021. The oral presentation, titled TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results, will take place on June 4, 2021, while the poster presentation, Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma or chronic lymphocytic leukemia, is set for June 7, 2021. Both investigational therapies target cancer with unmet medical needs and have received various FDA designations, emphasizing their potential in oncology.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) has appointed Chase Leavitt as General Counsel, effective April 12, 2021. Leavitt brings extensive legal experience from leading biotech and technology firms, which is expected to bolster Oncternal's growth trajectory.
Leavitt's responsibilities will include navigating legal compliance and governance as the company develops its ROR1-targeting therapies and other oncology products. He received a B.S. and J.D. from the University of Southern California, adding valuable expertise to Oncternal's leadership team.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced promising interim results from a Phase 1b trial of cirmtuzumab combined with paclitaxel in HER2-negative breast cancer, showing a 57% partial response rate among evaluable patients. In preclinical studies, cirmtuzumab demonstrated single-agent efficacy and enhanced effects with standard chemotherapies against high-grade serous ovarian and endometrial cancers. Additionally, investigational selective androgen receptor degraders showed inhibition of tumor growth in androgen receptor-positive triple-negative breast cancer models. The company continues to advance its clinical programs.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the granting of an inducement award to new Senior VP of Human Resources, Anita Wiseth, on March 18, 2021. The award includes options for 90,000 shares at an exercise price of $8.36, vesting over four years. This grant, part of Oncternal’s 2021 Employment Inducement Incentive Award Plan, was approved by an independent compensation committee in compliance with Nasdaq regulations. The company focuses on developing novel oncology therapies targeting significant unmet medical needs.
Oncternal Therapeutics (Nasdaq: ONCT) reported encouraging interim results for cirmtuzumab combined with ibrutinib in its ongoing Phase 1/2 study for mantle cell lymphoma (MCL), showing a 47% complete response (CR) rate versus a historical 20% CR. The company is advancing ROR1-targeting CAR-T therapies and has two durable responses reported in Ewing sarcoma patients treated with TK216. Financially, Oncternal raised $125 million in 2020 to support its pipeline, with a net loss of $17.2 million for the year and $116.7 million cash on hand as of December 31, 2020.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) will report its fourth quarter and full year 2020 financial results on March 11, 2021, post-market. A webcast will follow at 2:00 p.m. PT for management to discuss the results and provide a business update. Oncternal is focused on developing novel oncology therapies addressing unmet medical needs, with ongoing clinical studies for cirmtuzumab and TK216. The company's primary aim is to tap into promising biological pathways involved in cancer progression.
Oncternal Therapeutics (Nasdaq: ONCT) will participate in two significant virtual conferences in March 2021. The first is the H.C. Wainwright Global Life Sciences Conference on March 9, starting at 7:00 AM ET, with James Breitmeyer presenting. The second event is the Oppenheimer 31st Annual Healthcare Conference on March 16, at 4:30 PM ET, also featuring Breitmeyer. Both presentations will be available for streaming, and links can be found on Oncternal's investor website. The company focuses on developing innovative oncology therapies.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced the granting of an inducement award to Christy Stolzer, its new Associate Director of Drug Safety, on February 22, 2021. The award includes options to purchase 60,000 shares of common stock at an exercise price of $7.20 per share, vesting over four years. This grant adheres to Oncternal's 2021 Employment Inducement Incentive Award Plan, aimed at attracting new employees. The options were approved by the independent compensation committee as required by Nasdaq regulations.
Oncternal Therapeutics appointed Dr. Rosemary Mazanet to its Board of Directors, effective January 27, 2021. She brings extensive oncology drug development experience, having led initiatives at Amgen and serving in leadership roles in various biopharma companies. Dr. Mazanet's expertise is expected to enhance Oncternal's ongoing projects, including cirmtuzumab and ROR1 CAR-T programs. Oncternal focuses on innovative oncology therapies targeting unmet medical needs, with clinical trials underway for its candidates.